OKYO Pharma (OKYO) Net Cash Flow (2024 - 2026)

OKYO Pharma's (OKYO) quarterly Net Cash Flow came in at $10.4 million in Q1 2026, up 636.28% quarter-over-quarter from -$1.9 million in Q4 2025.

Analysis

OKYO Pharma (OKYO) Net Cash Flow (2024 - 2026) Analysis & Trends

OKYO Pharma (OKYO) has reported Net Cash Flow for 3 consecutive years, with $10.4 million the latest figure, recorded in Q1 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Cash Flow (Qtr)
1	Amgen	236.37 Bn	222.38 Bn	7.24 Bn	1.95 Bn
2	Gilead Sciences	187.38 Bn	184.12 Bn	6.22 Bn	-4.43 Bn
3	Vertex Pharmaceuticals	138.36 Bn	130.51 Bn	2.84 Bn	652.90 Mn
4	Regeneron Pharmaceuticals	85.09 Bn	77.10 Bn	3.93 Bn	-504.30 Mn
5	Argenx Se	63.93 Bn	58.75 Bn	1.37 Bn	-
6	Moderna	58.07 Bn	52.94 Bn	52.00 Mn	-183.00 Mn
7	Alnylam Pharmaceuticals	35.59 Bn	32.28 Bn	992.69 Mn	-496,000.00
8	Biogen	32.63 Bn	31.34 Bn	1.96 Bn	-2.09 Bn
9	Insmed	27.57 Bn	26.41 Bn	358.27 Mn	-37.14 Mn
10	OKYO Pharma	1.06 Bn	1.06 Bn	-	10.43 Mn

Historic Data

Download Data